The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Rusfertide (PTG-300) treatment in phlebotomy-dependent polycythemia vera patients.
 
Ronald Hoffman
Consulting or Advisory Role - Novartis; Protagonist Therapeutics
Research Funding - Novartis (Inst); Scholar Rock (Inst); Scholar Rock (Inst); Turning Point Therapeutics (Inst)
 
Yelena Ginzburg
No Relationships to Disclose
 
Marina Kremyanskaya
No Relationships to Disclose
 
Sarita Khanna
Employment - Protagonist Therapeutics
Stock and Other Ownership Interests - Protagonist Therapeutics
 
Nishit Modi
Employment - Protagonist Therapeutics
Stock and Other Ownership Interests - Protagonist Therapeutics
Patents, Royalties, Other Intellectual Property - Protagonist Therapeutics
 
Frank Horace Valone
Stock and Other Ownership Interests - Protagonist Therapeutics
Consulting or Advisory Role - Protagonist Therapeutics
 
Paula G. O'Connor
Employment - Protagonist Therapeutics
Stock and Other Ownership Interests - Protagonist Therapeutics
 
Suneel Gupta
Employment - Protagonist Therapeutics
Leadership - Protagonist Therapeutics
Stock and Other Ownership Interests - Protagonist Therapeutics
Patents, Royalties, Other Intellectual Property - Protagonist Therapeutics
 
Samuel R. Saks
Stock and Other Ownership Interests - Protagonist Therapeutics
Consulting or Advisory Role - Protagonist Therapeutics